Cancer Institute A national cancer institute
designated cancer center

Iris C. Gibbs, MD, FACR

Publication Details

  • A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood NEURO-ONCOLOGY Cohen, K. J., Gibbs, I. C., Fisher, P. G., Hayashi, R. J., Macy, M. E., Gore, L. 2013; 15 (6): 783-787


    Background Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas. Methods We conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable. Results ATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation. Conclusions The recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.

    View details for DOI 10.1093/neuonc/not021

    View details for Web of Science ID 000319476700015

    View details for PubMedID 23460318

Stanford Medicine Resources:

Footer Links: